HSDT חוב כולל להון Helius Medical Technologies Inc.

Helius Medical (HSDT) relies on external contractors for electronics manufacturing and physician support to optimize distribution. The company is developing portable brain stimulation systems, expanding the range of targeted pathologies to minimize development risks. Patents and FDA approval create a defensive barrier, limiting the entry of new players. The market's valuation dynamics for the asset, based on the total debt-to-equity ratio, is 0.00.

This metric measures the degree of the company's dependence on external creditors by comparing total liabilities to equity to assess financial stability. For Helius Medical (HSDT), given its monopoly position in the neurostimulation niche, this balance determines the ability to invest in the premium PoNS product, which is clearly reflected in the debt-to-equity ratio chart.